BMO Capital analyst Evan David Seigerman downgraded BioNTech (NASDAQ: BNTX) from Outperform to Market Perform with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades